Jasper Therapeutics Inc (NASDAQ:JSPR) finished Wednesday with an addition of $0.02 to close at $0.70, an upside of 3.40 percent. An average of 1,220,460 shares of common stock have been traded in the last five days. There was a fall of -$0.0710 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 659,480 shares traded, while the 50-day average volume stands at 369,742.
JSPR stock has decreased by -47.37% in the last month. The company shares reached their 1-month lowest point of $0.6249 on 09/26/23. With the stock rallying to its 52-week high on 01/03/23, shares of the company touched a low of $0.39 and a high of $3.80 in 52 weeks. It has reached a new high 1 time so far this year and achieved 44.96% or $0.2171 in price. In spite of this, the price is down -81.58% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
JSPR stock investors should be aware that Jasper Therapeutics Inc (JSPR) stock had its last reported insider trading activity 107 days ago on Jun 13. In this transaction, the insider spent $14,915. Director, French Anna Louise, disposed of 7,000 shares at a price of $1.48 on Apr 14. The insider now owns more than $10,360 worth of shares. Prior to that, Director EMSTER KURT VON went on to Sale 9,075 shares at $1.49 each on Apr 13. An amount of $13,524 was transacted.
Valuation Metrics
Jasper Therapeutics Inc (JSPR) stock’s beta is 2.05. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.70.
Financial Health
The quick ratio of Jasper Therapeutics Inc for the three months ended June 29 was 13.22, and the current ratio was 13.22, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.02 and a total debt to equity ratio of 0.03 for the quarter ending June 29. Its gross profit as reported stood at $13.51 million compared to revenue of $51.2 million.
Earnings Surprise
The company posted a net income of -$16.08 million in the quarter, while revenues of -$14.26 million were grew 35.32%. The analyst consensus anticipated Jasper Therapeutics Inc’s latest quarter earnings to come in at -$0.15 per share, but it turned out to be -$0.15, a 0.00% surprise. Shareholders own equity worth $110.8 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Jasper Therapeutics Inc (JSPR) price momentum. RSI 9-day as of the close on 27 September was 26.35%, suggesting the stock is oversold, with historical volatility in this time frame at 85.66%.
As of today, JSPR’s price is $0.7236 -9.21% or -$0.0710 from its 5-day moving average. JSPR is currently trading -46.56% lower than its 20-day SMA and -52.70% lower than its 100-day SMA. However, the stock’s current price level is -52.38% below the SMA50 and +24.40% above the SMA200.
The stochastic %K and %D were 16.54% and 17.54%, respectively, and the average true range (ATR) was 0.0979. With the 14-day stochastic at 22.42% and the average true range at 0.0967, the RSI (14) stands at 26.09%. The stock has reached -0.0583 on the 9-day MACD Oscillator while the 14-day reading was at -0.0700.
Analyst Ratings
CapitalOne launched coverage on Jasper Therapeutics Inc (NASDAQ: JSPR) in its analyst report released on August 11, 2023. The firm assigned the stock an Overweight rating. The consensus rating for Jasper Therapeutics Inc (JSPR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JSPR, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 3 others rate it as a “buy”.
What is JSPR’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $8.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for Jasper Therapeutics Inc (JSPR) stock is $7.00.
